TY - JOUR
T1 - Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy
AU - Graves, Stephen A.
AU - Hobbs, Robert F.
N1 - Funding Information:
Funding: Dr. Graves and Dr. Hobbs are currently supported by grant awards from the National Institutes for Health in project areas relating to the subject matter of this paper. Conflicts of Interest Disclosure: Dr. Graves has no conflicts of interest to disclose. Dr. Hobbs is a paid consultant for Radiopharmaceutical Imaging and Dosimetry, LLC (RAPID). RAPID has licensed the intellectual property of Dr. Hobbs, and Dr. Hobbs is the recipient of an SBIR subaward from RAPID.
PY - 2021/1
Y1 - 2021/1
N2 - Radiopharmaceutical therapy (RPT) has grown rapidly over the last decade for treatment of numerous cancer types. Dosimetric guidance, as with other radiotherapy modalities, has benefitted patients by reducing the incidence of side effects and improving overall survival in populations treated under this paradigm. Development of tools and techniques for dosimetry-guided therapy is ongoing, with numerous the Food and Drug Administration-cleared products reaching the U.S. market in 2019. Safe use of commercial dosimetry platforms requires a deep understanding of the underlying physical principles and thoroughly vetted input data. Likewise, interpretation of dosimetry results relies on an understanding of radiobiological principles, and the principles of uncertainty propagation. In this article, we review strategies commonly employed for dosimetry-guided RPT – including quantitative imaging, dose calculation methods, and modeling of dose across time-points. Additionally, we review recent literature evidence (2013-2020) demonstrating the efficacy of personalized RPT.
AB - Radiopharmaceutical therapy (RPT) has grown rapidly over the last decade for treatment of numerous cancer types. Dosimetric guidance, as with other radiotherapy modalities, has benefitted patients by reducing the incidence of side effects and improving overall survival in populations treated under this paradigm. Development of tools and techniques for dosimetry-guided therapy is ongoing, with numerous the Food and Drug Administration-cleared products reaching the U.S. market in 2019. Safe use of commercial dosimetry platforms requires a deep understanding of the underlying physical principles and thoroughly vetted input data. Likewise, interpretation of dosimetry results relies on an understanding of radiobiological principles, and the principles of uncertainty propagation. In this article, we review strategies commonly employed for dosimetry-guided RPT – including quantitative imaging, dose calculation methods, and modeling of dose across time-points. Additionally, we review recent literature evidence (2013-2020) demonstrating the efficacy of personalized RPT.
UR - http://www.scopus.com/inward/record.url?scp=85090980104&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090980104&partnerID=8YFLogxK
U2 - 10.1016/j.semradonc.2020.07.008
DO - 10.1016/j.semradonc.2020.07.008
M3 - Review article
C2 - 33246635
AN - SCOPUS:85090980104
VL - 31
SP - 37
EP - 44
JO - Seminars in Radiation Oncology
JF - Seminars in Radiation Oncology
SN - 1053-4296
IS - 1
ER -